BTIG Research lowered shares of Vapotherm (NYSE:VAPO – Get Rating) from a buy rating to a neutral rating in a research note issued to investors on Thursday, The Fly reports.
Several other research firms also recently commented on VAPO. Piper Sandler decreased their price objective on shares of Vapotherm from $2.50 to $2.00 and set an underweight rating on the stock in a report on Thursday. William Blair cut shares of Vapotherm from an outperform rating to a market perform rating in a research report on Thursday. Canaccord Genuity Group downgraded shares of Vapotherm from a buy rating to a hold rating and decreased their price target for the company from $12.00 to $5.00 in a research note on Friday, May 6th. Finally, Canaccord Genuity Group cut shares of Vapotherm from a buy rating to a hold rating and dropped their price objective for the stock from $12.00 to $5.00 in a research note on Friday, May 6th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company's stock. Based on data from MarketBeat.com, Vapotherm presently has a consensus rating of Hold and a consensus target price of $4.75.
Get Vapotherm alerts:Vapotherm Price Performance
Shares of VAPO opened at $1.80 on Thursday. The company has a market cap of $47.82 million, a price-to-earnings ratio of -0.49 and a beta of -0.22. Vapotherm has a 1-year low of $1.66 and a 1-year high of $31.87. The company's fifty day simple moving average is $2.56 and its 200 day simple moving average is $7.83. The company has a current ratio of 5.29, a quick ratio of 3.75 and a debt-to-equity ratio of 7.04.
Insider Transactions at Vapotherm
In other Vapotherm news, Director Anthony L. Arnerich purchased 10,000 shares of the firm's stock in a transaction dated Wednesday, June 1st. The shares were bought at an average price of $3.06 per share, for a total transaction of $30,600.00. Following the purchase, the director now owns 53,374 shares in the company, valued at approximately $163,324.44. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders bought 35,000 shares of company stock valued at $106,100. Company insiders own 12.80% of the company's stock.Institutional Trading of Vapotherm
Hedge funds and other institutional investors have recently modified their holdings of the stock. Prescott General Partners LLC raised its position in Vapotherm by 45.0% in the first quarter. Prescott General Partners LLC now owns 2,557,243 shares of the company's stock valued at $35,546,000 after purchasing an additional 793,504 shares during the last quarter. Crow s Nest Holdings LP raised its holdings in Vapotherm by 180.1% in the 1st quarter. Crow s Nest Holdings LP now owns 1,544,850 shares of the company's stock valued at $21,473,000 after buying an additional 993,350 shares during the last quarter. Hound Partners LLC raised its holdings in Vapotherm by 2.7% in the 4th quarter. Hound Partners LLC now owns 1,402,987 shares of the company's stock valued at $29,056,000 after buying an additional 37,135 shares during the last quarter. State Street Corp raised its holdings in Vapotherm by 7.3% in the 1st quarter. State Street Corp now owns 748,238 shares of the company's stock valued at $10,401,000 after buying an additional 50,613 shares during the last quarter. Finally, Pier Capital LLC raised its holdings in Vapotherm by 29.4% in the 1st quarter. Pier Capital LLC now owns 588,595 shares of the company's stock valued at $8,181,000 after buying an additional 133,791 shares during the last quarter. Institutional investors own 69.67% of the company's stock.
Vapotherm Company Profile
(Get Rating)
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Read More
- Get a free copy of the StockNews.com research report on Vapotherm (VAPO)
- Electric Vehicles Can Drive Alcoa Stock Higher
- Can Airbnb Still Thrive in a Recession?
- What to Expect from the Markets in a Recession
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- MarketBeat: Week in Review 8/1 – 8/5
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.